We have developed and validated a non-invasive method to estimate the clearance of cerebrospinal fluid (CSF) from the brain. This study tests the hypothesis that reduced CSF clearance is predictive of a) future amyloid lesions, b) brain atrophy, and c) cognitive decline in healthy elderly adults or those with Mild Cognitive Impairment (MCI).
Measuring brain CSF clearance with novel, experimental imaging techniques may advance the understanding of Alzheimer’s disease (AD) progression at its earliest stages.
All subjects will be enrolled at Weill Cornell Medicine. Study participation consists of 3-5 visits, lasts approximately two years and involves: 1) medical assessment with neurologist, 2) surveys assessing subjective health and well-being, 3) cognitive testing, 4) brain MRI, 5) amyloid PET-CT (FDA approved), 6) tau PET-CT, routine blood & urine analyses, donation of blood for research purposes. The visits occur using telehealth technology, and 3-5 in-person at the Weill Cornell Medicine Clinical and Translational Science Center (CTSC) and the Citigroup Biomedical Imaging Center (CBIC).